Recommended routine schedule of administration of conjugate Haemophilus influenzae type b vaccine for children in the United States

Recommended routine schedule of administration of conjugate Haemophilus influenzae type b vaccine for children in the United States

Primary series (<12 months of age)	Booster (≥12 months of age)
2, 4, and 6 months for ActHIB, Hiberix, DTaP-IPV/PRP-T (Pentacel), or DTaP-IPV-Hib-HepB (Vaxelis)	12 through 15 months for PRP-OMP, ActHIB, Hiberix, or DTaP-IPV/PRP-T
2 and 4 months for PRP-OMP

DTaP: diphtheria tetanus-toxoid-acellular pertussis vaccine; IPV: inactivated polio vaccine; PRP-T: polyribosylribitol phosphate conjugated to tetanus toxoid; Hib: Haemophilus influenzae type b; HepB: hepatitis B; PRP-OMP: polyribosylribitol phosphate conjugated to the outer membrane protein complex of Neisseria meningitidis.

Data from:

Centers for Disease Control and Prevention. Child and adolescent immunization schedule. Recommendations for ages 18 years or younger, United States, 2023. Available at: www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html (Accessed on February 16, 2023).
Oliver SE, Moore KL. Licensure of a diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate, and hepatitis B vaccine, and guidance for use in infants. MMWR Morb Mortal Wkly Rep 2020; 69:136.

Graphic 77170 Version 25.0

خرید پکیج

Recommended routine schedule of administration of conjugate Haemophilus influenzae type b vaccine for children in the United States